SS-31 (Elamipretide)
SS‑31 (Elamipretide) accumulates in the inner mitochondrial membrane where it binds cardiolipin, stabilises cristae architecture and respiratory super-complexes, and reduces electron leak–driven ROS production. It has been studied in cardiac and renal ischemia-reperfusion injury, mitochondrial myopathies, skeletal-muscle aging and systemic mitochondrial dysfunction, with the goal of preserving ATP output, limiting oxidative damage and improving organ recovery under stress.
Research areas & putative benefits
Where SS‑31 is deployed within mitochondrial and organ-protection research.
- Cardiac ischemia-reperfusion injury, myocardial infarction and heart failure models.
- Renal ischemia, acute kidney injury and renal artery stenosis revascularisation studies.
- Primary mitochondrial myopathy, Barth syndrome and skeletal-muscle fatigue/aging.
- Broader systemic mitochondrial dysfunction and multi-organ stress paradigms.
Mechanism stack
Core mechanisms behind SS‑31’s mitochondrial and organ-protective profile.
SS‑31 is a small, positively charged tetrapeptide that concentrates on the inner mitochondrial membrane, binding to cardiolipin and stabilising its interaction with electron transport chain complexes.
By preserving cardiolipin-dependent super-complex organisation, SS‑31 enhances electron flow, increases ATP production per oxygen consumed and reduces electron leak that would otherwise form superoxide and downstream ROS.
SS‑31 lowers mitochondrial ROS production, protects membrane lipids and proteins from peroxidation, and inhibits opening of the mitochondrial permeability transition pore, limiting swelling and cell death under acute stress.
In models such as Barth syndrome, SS‑31 improves mitochondrial cristae morphology and normalises markers of excessive mitophagy and fission, contributing to more resilient mitochondrial networks.
Evidence snapshot
Selected findings from SS‑31 mitochondrial and organ-protection studies.
| Model / context | Observation | Relevance |
|---|---|---|
|
Renal ischemia-reperfusion and renal artery stenosis
Kidney
|
SS‑31 reduces mitochondrial swelling, inhibits permeability transition pore opening, improves ATP recovery and decreases tubular apoptosis; in pilot human trials during renal revascularisation it attenuates post-procedural hypoxia and improves renal blood flow and function. | Supports use as an adjunctive mitochondrial-protection strategy during high-risk renal procedures. |
|
Cardiac ischemia and Barth syndrome models
Heart / cardiolipin disorder
|
SS‑31 improves mitochondrial cristae structure, restores respiratory efficiency, reduces infarct size and improves cardiac function in myocardial infarction and tafazzin-deficient (Barth syndrome) mouse models. | Demonstrates both structural and functional cardiac protection in settings of cardiolipin dysfunction. |
|
Mitochondrial myopathy and muscle aging
Muscle / performance
|
Treatment improves mitochondrial respiration, lowers oxidative damage markers and increases endurance or exercise capacity in animal models with impaired mitochondrial function. | Links mitochondrial targeting to practical improvements in skeletal-muscle performance. |
|
Cellular and proteomic studies
Mechanistic
|
SS‑31 interacts with multiple cardiolipin-binding proteins in the electron transport chain and 2‑oxoglutarate pathway, reduces ROS in stressed cells, and restores mitochondrial function in toxin-induced dysfunction models. | Provides a molecular interaction map explaining multi-faceted protective effects across tissues. |
Risk frame & unknowns
Open questions around SS‑31 translation and positioning.
- Large outcome trials in specific indications have shown mixed results despite favourable mechanistic and biomarker findings.
- Optimal dosing, route (IV vs SC) and timing differ between acute ischemia settings and chronic mitochondrial diseases.
- Long-term use outside of controlled trials is not yet extensively documented across diverse populations.
- Stacking SS‑31 with other mitochondrial-targeted agents, antioxidants or metabolic modulators could create complex interactions that are not fully understood.
This dossier summarizes mechanistic, preclinical and clinical findings on SS‑31 (Elamipretide) for scientific and educational purposes only. It does not provide medical advice, treatment guidance or dosing recommendations.